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OKT3 first.dose reaction: Association with T cell subsets and cytokine
release. Use of the monoclonal antibody OKT3 to prevent or treat
allograft rejection has become commonplace. Its administration is often
complicated by serious side effects, usually occurring within one to two
hours after OKT3 is given, and is termed first-dose reaction. The
mechanism underlying these signs and symptoms is poorly defined, but
may be related to cytokine release. Twenty-three kidney or kidney!
pancreas transplant recipients received OKT3 as treatment of acute
rejection. Signs and symptoms occurring after the first dose were
observed and quantitated prospectively, and a reaction score was
calculated. Blood was drawn immediately before, and at 2 and 24 hours
after the first dose of OKT3 for determination of interleukin-2 (1L2),
interferon-gamma (IFNy), and tumor necrosis factor-alpha (TNFa)
levels, and flow cytometric analysis of T cell subsets. Two groups were
defined based on severity of first-dose reaction. Group I patients (N =
11) had very mild reactions (reaction score  3); Group 2 patients (N =
12) had more severe reactions (score  5). All patients demonstrated a
significant rise in serum TNFa from baseline to two hours after OKT3
(9 3 pg/mI to 378 54 pg/mI, P < 0.0001), and there was significant
correlation between reaction scores and two-hour TNFa levels (P =
0.005). Group 2 patients had higher TNFa levels at two hours than did
Group 1 patients (484 75 pg/mI vs. 263 62 pglml, P = 0.04). Levels
of 1L2 and IFNy were not elevated at any sampling time. Group 2
patients also had significantly greater numbers of circulating CD3+ (521
114 vs. 257 58, P = 0.04) and CD4+ (226 45 vs. 87 23, P =
0.01) lymphocytes prior to OKT3 administration. In addition, pre-
OKT3 CD4+ levels correlated with reaction scores. These data impli-
cate TNFa, perhaps of activated T lymphocyte origin, as a key
mediator of the OKT3 first-dose reaction.
OKT3 monoclonal antibody (mAb), introduced clinically in
1986, has been a significant addition to the immunosuppressive
armamentarium, gaining widespread acceptance for both pro-
phylaxis and therapy of acute rejection in solid organ transplant
recipients [1—4]. Its efficacy derives from a unique ability to
modulate the CD3 portion of the T cell antigen receptor (TCR)
complex, deleting it from the membrane of T lymphocytes, thus
rendering the cells immunologically impotent [5]. This effect is
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accompanied by opsonization of CD3 + cells, with their subse-
quent removal by the reticuloendothelial system. Unfortu-
nately, use of OKT3 is frequently accompanied by a constella-
tion of side effects which may cause considerable morbidity in
patients, and distress in their physicians [1—6]. Usually occur-
ring within one to two hours of the first or second dose, adverse
responses range in severity from very mild to life-threatening,
and have resulted in at least two deaths [11. Previously, these
signs and symptoms have been referred to as "influenza-like"
[2, 7]. Our patients experiencing such reactions are often more
vivid in their descriptions: "I feel like I've been hit by a truck"
and "this stuff could make a dead man move." Most typically,
however, "first-dose reactions" involve some combination of
fever, chills, dyspnealwheezing, tachycardia, hypotension, and
nausea/vomiting [6], and occur in 50 to 80% of patients receiv-
ing OKT3.
Early reports of OKT3 administration attributed first-dose
reaction to release of "endogenous pyrogens" following exten-
sive lysis of peripheral blood lymphocytes [8], a mechanism
similar to that thought responsible for symptomatology ob-
served in patients receiving polyclonal anti-lymphocyte prepa-
rations [9]. Such a mechanism, however, seems unlikely since
other lympholytic regimens may not cause similar reactions [10,
11]. In vitro, OKT3 has long been known to stimulate T
lymphocyte activation and proliferation, with associated cyto-
kine synthesis and release [12—14]. In several recent publica-
tions, clinical syndromes remarkably similar to OKT3 first-dose
reaction have been linked to cytokines [15—17]. Recently, two
European groups have documented a rise in plasma and serum
levels of interleukin-2 (1L2), interferon-gamma (IFNy), and
tumor necrosis factor-alpha (TNFa) within one hour of OKT3
administration [18, 191. Thus, some now refer to first-dose
reaction as "cytokine release syndrome," and postulate that it
may reflect T cell stimulation rather than lysis [20, 21].
This prospective study was initiated to explore the relation-
ship between symptomatology observed following OKT3 ad-
ministration and the cytokines IL2, IFN7, and TNFa. Our
results establish an association of OKT3 first-dose reaction with
cytokine release, primarily TNFa, and support a role for
stimulated T lymphocytes as the source of such mediators.
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Methods
Study patients were selected from all renal transplant recip-
ients who received OKT3 (Orthoclone® OKT3, Ortho Pharma-
ceutical Corporation, Raritan, New Jersey, USA) as inpatients
at the University of Alabama at Birmingham (UAB) between
August 1988 and March 1989. Twenty-three patients experienc-
ing acute rejection were included for subsequent analysis: 21
had received kidney transplants, and two had received com-
bined kidney/pancreas grafts. A diagnosis of acute rejection
was made by clinical criteria which included declining renal
function, and was supported by either radionuclide scan or
renal biopsy. All but two subjects were given OKT3 as "res-
cue" therapy, having failed to respond to high-dose methyl-
prednisolone (>1 g) in the days prior to mAb administration.
The protocol was approved by the Institutional Review Board
for Human Use at UAB.
Study patients were observed and interviewed at frequent
intervals during the first day of OKT3 therapy. Side effects were
noted and quantitated by an investigator (RSG or TP), with
severity graded as follows: absent = 0, mild = 1, moderate = 2,
and severe = 3. A total reaction score was calculated based on
severity of fever, headache, dyspnea, and rigor, and ranged
from 0 to 12. This scoring system is similar to one described by
Michie et al [161. Retrospectively, subjects were divided into
two groups based on severity of first-dose reaction. Group 1 (N
= ii) patients experienced few manifestations of first-dose
reaction, with total scores 3 (temperature  38.0°C—l
patient, moderate-to-severe dyspnea—4, moderate-to-severe
headache—i, rigor—l). In contrast, all patients in Group 2 (N
= 12) had reaction scores of 5, with correspondingly more
severe side effects (temperature  38.0°C—9 patients, moder-
ate-to-severe dyspnea—7, moderate-to-severe headache—7,
rigor—9). The two groups did not differ in age, sex, race, donor
source, HLA match, original disease, or time from transplan-
tation to OKT3 administration (Table 1). One patient in Group
1 and two patients in Group 2 had received their allografts more
than one year before this study; however, the remainder of
study subjects were six weeks or less post-transplant.
The "quadruple" immunosuppressive protocol used in these
patients has been described elsewhere [221. Briefly, induction
immunosuppression included Minnesota antilymphoblast glob-
ulin (MALG) 20 mg/kg/day from day 1 until the serum creati-
nine fell to 265 imol/liter. At that time, oral cyclosporine
(CsA) was started at a dose of 5 to 10 mg/kg/day, with dosing
altered to maintain trough levels at 200 to 500 pg/ml (whole
blood, polyclonal radioimmunoassay). When therapeutic CsA
levels were achieved, MALG was discontinued, usually result-
ing in a two to three day overlap of CsA and MALG. Azathio-
prine (Aza; 4 mg/kg) and methylprednisolone (MP; 5 mg/kg)
were administered perioperatively, and doses of 25 mg/day and
30 mg/day, respectively, were continued until MALG was
stopped. Thereafter, maintenance immunosuppression con-
sisted of CsA, azathioprine (100 mg/day), and prednisone (30
mg/day, with a weekly taper of 2.5 mg/dose to 0.1 to 0.15
mg/kg/day). In Group 2, 10 of 12 patients were receiving CsA at
the time OKT3 was started, versus 10 of 11 in Group 1. In those
subjects on CsA, trough levels were not significantly different
between groups (Table 1). Likewise, there was no difference in
MALG dosage or interval between MALG and OKT3 therapy.
Table 1. Characteristics of study patients receiving OKT3
Group 1 Group 2
(N=11) (N=12)
Age years 39.4 2.2 41.4 2.9
Sex male/female 8/3 7/5
Race black/white 4/7 5/7
Original disease
Hypertension 2 7
Diabetes mellitus 5 2
Glomerulonephritis 4 1
Other 0 2
Donor source (cadaver/living) 10/1 11/1
HLA match (AB/DR) 1.1/0.7 1.1/0.8
Time since transplant (months)' 0.97 0.1 0.92 0.1
Days since last MALG dos&' 19 2.9 19 2.7
MP dose g/patientc 2.8 0.4 3.7 0.4
CsA level pg/ml' 240 51 162 32
Serum creatinine pnol/liter 377 53 318 27
Abbreviations are: MALG, Minnesota antilymphoblast globulin; MP,
methylprednisolone; CsA, cyclosporine.
a There were no significant differences between groups in any param-
eter other than reaction score. Sex, race, original disease, and donor
source are absolute numbers; HLA match is mean value; all other
values are expressed as mean SEM
b Not including 3 patients transplanted more than one year prior to
study
MP dose expressed as grams administered per patient during the
week prior to OKT3
d CsA level, measured by whole-blood radioimmunoassay, is a
24-hour trough value
OKT3 was administered intravenously (i.v.) at a dose of 5
mg/day for 10 to 14 days. Premedication (diphenhydramine 50
mg and acetaminophen 650 mg) was given 30 minutes before
each dose. Prior to the first and second doses only, patients
received MP 250 mg i.v., with subsequent doses preceded by 30
mg infusions of MP. The first dose was followed at one hour by
hydrocortisone 100 mg i.v. During OKT3 treatment, Aza was
decreased to 25 mg/day, and CsA and prednisone were with-
held. Maintenance immunosuppression was resumed three to
four days prior to completion of OKT3.
Blood samples were drawn immediately before OKT3 admin-
istration, and 2 and 24 hours after the first dose. Sera for
cytokine analysis were stored at <0°C for subsequent assay.
Serum levels of TNFa were quantitated by immunoradiometric
assay (sensitivity: 5 pg/ml, Medgenix, Billerica, Massachusetts,
USA). 1L2 was quantitated by both radioimmunoassay (sensi-
tivity: 1 U/ml, Medgenix) and enzyme-linked immunosorbent
assay (ELISA; sensitivity: 1 U/ml, Genzyme, Boston, Massa-
chusetts, USA). IFNy assays were also performed with ELISA
(sensitivity: 1 U/ml), using mouse monoclonal anti-human IFNy
antibodies (Chemicon International, Inc., El Segundo, Califor-
nia, USA), and recombinant human IFNy (Genzyme) as stan-
dard. In addition, blood was drawn from six transplant recipi-
ents experiencing acute rejection on days 1 and 2 of high-dose
methylprednisolone therapy, with sera subsequently assayed
for TNFa, 1L2, and IFN7.
Peripheral blood lymphocytes were isolated via Ficoll-Paque
separation from fresh, heparinized blood in 16 subjects (Group
1: 9 patients; Group 2: 7 patients). Flow cytometry was per-
formed with a Becton Dickinson FACScan® system, and mono-
clonal antibodies of the Leu series (Becton Dickinson, Moun-
tain View, California, USA): Anti-Leu 2 (CD8), -Leu 3 (CD4),
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Fig. 1. Serum cytokine levels in study patients at baseline, 2 and 24
hours after first dose of OKT3. Values are mean SEM. Abbreviations
are: TNFa, tumor necrosis factor-alpha; 1L2, interleukin-2; IFN7,
interferon-gamma. A. Symbols are (_) all patients; ( ) Group 1;
(---). B. Symbols are: (---) 1L2; (—) IFN.
-Leu 4 (CD3), -Leu 7 (CD57—a marker of natural killer [NK]
activity), and -Leu 17 (CD38, an antigen expressed on "acti-
vated" T cells, as well as some subsets of B lymphocytes
[Jackson AL, Chen JC, Pali ES, Warner NL, unpublished
observations.]). Absolute cell numbers were calculated from
manually performed differential white cell counts. In those
patients who did not have a complete blood count (CBC) with
manual differential performed at two hours, absolute counts
were calculated using two hour flow cytometry results with the
first available CBC post-OKT3 (usually 24 hours).
Statistical analysis was performed using a microcomputer
(Macintosh SE, Apple Computer, Cupertino, California, USA)
and a standard statistical package (StatworksTM, Cricket Soft-
ware, Malvern, Pennsylvania, USA). Unpaired and paired
Student's t-tests were used to compare intergroup differences
and timed changes, respectively. Correlation was performed by
the Spearman method. A P value less than 0.05 was interpreted
as significant. Values are expressed as mean SEM.
Results
TNFa levels rose from a baseline of 9 3 pg/mi, to 378 54
pg/mi at two hours (P < 0.0001; Fig. 1). By 24 hours, levels had
returned to near baseline (52 9). There were no intergroup
differences in TNFa levels at 0 and 24 hours. However, the
groups differed at two hours post-OKT3; the serum concentra-
tion of TNFa rose to 484 75 pg/mi in Group 2 patients, with
more severe first dose reactions, versus 263 62 in Group 1
subjects (P = 0.04). In addition, significant correlation was
noted between levels of TNFa at two hours and reaction scores
of patients in both groups (Fig. 2; r = 0.57, P = 0.005). A two
hour TNFa level  350 pg/mi was 75% predictive of severe first
dose reaction; levels <350 predicted a mild or absent reaction
73% of the time. No significant elevation of IL2 or IFN7 levels
was noted at any sampling time. In the six patients receiving
only glucocorticoids as anti-rejection therapy, significant levels
of TNFa, 1L2, and IFN7 were not detected.
OKT3 treatment profoundly changed the total neutrophil and
lymphocyte counts, with neutrophilia and lymphopenia evident
at two hours (Table 2). Likewise, T cells expressing antigens
CD3, CD4, CD8, CD57, and CD38 had essentially disappeared
from the circulation by two hours post-OKT3. Although pa-
tients in both groups had manifested similar drops in circulating
T cell counts by two hours, the groups differed in CD3 + (Group
1: 257 58 vs. Group 2: 521 114, P =0.04) and CD4+ (Group
1: 87 23 vs. Group 2: 226 45, P = 0.01) cells prior to OKT3
dosing (Fig. 3). There was significant correlation between the
number of CD4+ cells prior to OKT3 and reaction scores (r =
0.6, P = 0.014); however, no correlation of CD4+ cells with
two hour TNFa levels was seen (r = 0.25, P = 0.36). CD3+
counts before OKT3 also did not correlate with either TNFs
levels or reaction scores. These parameters in individual pa-
tients are reported in Table 3.
The difference in pre-OKT3 levels of CD8+ cells approached
statistical significance (P = 0.13; Table 1). In addition, cells
bearing the antigen CD38, a marker of T lymphocyte activation,
were more numerous in Group 2 before OKT3, with a more
pronounced drop evident at two hours. These data did not,
however, achieve statistical significance. Lymphopenia and
neutrophilia persisted at 24 hours post-OKT3, as did depression
of all T cell subsets.
Discussion
OKT3 is highly effective in both prevention and reversal of
acute rejection in allograft recipients, and is now included in the
immunosuppressive protocols of many transplant centers.
However, first-dose reaction remains as a troublesome and
poorly understood phenomenon. The previously accepted eti-
ologic mechanism of release of mediators during cell lysis
inadequately explains this syndrome. The current study is the
first to correlate severity of first-dose reaction and cytokine
release, which we, and others [20, 21], suggest may result from
T cell activation rather than lysis.
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Fig. 2. Spearman correlation of post-OKT3 reaction score with serum
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Table 2. Cell counts in study patients before and 2 hours after first OKT3 dose
P
All patients Group 1 Group 2 GP 1 vs. 2
Total neutrophils
Ohrs 11674 863 11697 1161 11654 1316 ns
2 hrs 17043 1646 17692 2063 16448 2603 ns
Total lymphocytes
0 hrs 637 98 626 166 648 108 ns
2 hrs 184 40 221 49 150 63 ns
CD3 + (Leu 4)
Ohrs 372 66 257 58 521 114 0.04
2hrs 0 0 0
CD4+ (Leu 3)
0 hrs 148 29 87 23 226 45 0.01
2hrs 0 0 0
CD8+ (Leu 2)
0 hrs 158 38 105 34 220 66 0.13
2hrs 0 0 0
CD38+ (Leu 17)
0 hrs 253 58 201 84 313 79 0.36
2hrs 27 14 47 23 0 0.10
CD57+ (Leu 7)
0 hrs 79 22 88 35 68 25 ns
2hrs 0 0 0
Counts are reported as number of cells/s.d of blood.








Fig. 3. Absolute counts of T lymphocytes bearing surface antigens
CD3, CD4, and CD8 at baseline in OKT3-treated patients, by groups.
Statistical comparison is with unpaired Student's t-test. Values are
mean SEM. Symbols are: () Group 1; () Group 2.
symptoms associated with cytokines in other clinical situations.
The administration of lymphokine-activated killer (LAK) cells
with recombinant 1L2 (rIL2) to patients with advanced cancer
results in fever, chills, dyspnea, nausea, and malaise in more
than 80% of recipients [15]. Mier and coworkers recently found
no direct pyrogenic effect of rIL2, but rather that its infusion
increased serum levels of TNFa [23]. These investigators
postulated that TNFa caused the fever as well as other aspects
of the acute-phase response associated with 1L2 therapy. In
addition, TNFa is known to mediate endotoxin shock [16, 17],
and the magnitude of serum levels of TNFa has been correlated
with mortality in children with cerebral malaria [24]. In animal
studies, infusion of recombinant human TNF has resulted in
hypotension, pyrexia, tachycardia, pulmonary edema, and lym-
phopenia [25—27].
The concept of OKT3 administration resulting in cytokine
stimulation and release is not new. Early studies revealed the
potent mitogenic properties of OKT3 [12]. Subsequently, sev-
eral investigators observed anti-CD3 antibodies to directly
induce T cell activation in vitro [13, 28, 29]. Indeed, the ligand
defined by this monoclonal is the CD3 portion of the T cell
antigen receptor complex, present in the cell membrane of all
mature T lymphocytes, and intimately involved in cell activa-
tion [30, 311. The cytokines 1L2 and IFNy, products of T cell
activation, have been detected in supernatants of OKT3-stim-
ulated T lymphocytes [29, 32—34]. Granelli-Piperno, Andrus and
Steinman documented that OKT3 induces new cytokine syn-
thesis by T cells, demonstrating enhanced 1L2 and IFNy
mRNA production [34]. CsA and corticosteroids have been
shown to inhibit IL2 and IFNy synthesis in vitro [33, 35];
indeed, the immunosuppressive efficacy of CsA is thought to
reside in its ability to inhibit cytokine production by CD4+ I
cells [36].
In vivo evidence that anti-CD3 antibodies activate T lympho-
cytes has only recently been forthcoming. In a mouse model,
Hirsch and colleagues [37] found that the anti-CD3 mAb 145-
2C 11 stimulated IL2 receptor (IL2R) expression on T cells, and
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Table 3. Results of key parameters in individual study patients, by groups
Reaction score
Patient (0—12)





TH 0 127 5 80 Yes
RJ 3 528 38 300 Yes
RP 0 496 150 140 Yes
LA 2 357 204 20 Yes
CP 3 NA NA 680 No
DoH 3 107 45 525 Yes
DM 2 NA NA 240 No
DaH 2 34 16 50 Yes
LM 1 246 82 320 Yes
PG (KIP) 3 256 140 380 Yes
MB 3 159 106 160 No
Mean SEM 2.0 0.4 257 58 87 23 263 62
Group 2
WR 11 875 243 380 Yes
LD 10 NA NA 625 Yes
DA 5 365 155 575 Yes
RR 6 382 239 450 Yes
CM (K/P) 5 897 481 160 Yes
CK 6 NA NA 1075 Yes
CC 10 229 138 225 Yes
LS 5 714 158 360 Yes
LH 7 182 171 325 No
GR 8 NA NA 840 Yes
WT 6 NA NA 350 Yes
BD 11 NA NA 440 Yes
Mean SEM 7.5 0.7° 521 114 226 45° 484 75
Abbreviations are: TNFa, tumor necrosis factor alpha; K/P, Combined kidney/pancreas graft; NA, not available.
a Group 1 vs. Group 2, P < 0.05
b Serum creatinine less at end of course of OKT3 than at beginning
within two to three hours of injection. Interestingly, F(ab')2
fragments of the mAb did not stimulate either IL2R or CSF
production. Anti-CD3 antibody-dependent T cell activation
requires the presence of monocytes or other substrate to
facilitate cross linking of Fc domains of mAb molecules [29, 32].
Mitogenic effects may readily be observed with T cells and
monocytes are incubated with OKT3 in fetal calf serum. How-
ever, with human serum as medium, such effects are inhibited,
presumably by the presence of antibodies which bind to mono-
cyte Fc receptors [31]. Thus, interaction of Fc portions of the
OKT3 antibody with monocyte Fc receptors has been thought
essential to T cell proliferation, which has been presumed not to
occur in humans following administration of this agent.
Abramowicz et al [18] found elevated serum levels of 1L2,
IFNy, and TNFa in OKT3-treated patients premedicated with
azathioprine and 1 mg/kg methylprednisolone. The highest
TNFa levels occurred within one hour of the first OKT3 dose,
while 1L2 and IFN7 peaked slightly later (2 to 4 hours).
Following subsequent doses, no cytokine stimulation was
noted. Chatenoud et al [19] obtained similar results in three
patients pretreated with azathioprine alone. However, 14 pa-
tients who were given methylprednisolone in high doses (1 g)
prior to OKT3 showed no rise in 1L2 levels with the first dose.
Recently, Goldman and coworkers documented that premedi-
cation of OKT3 recipients with methylprednisolone at doses (8
mg/kg) higher than currently recommended by the manufac-
turer(l mg/kg) attenuated the rise in cytokines (especially IFNy
and TNFa, with less effect on 1L2) following the first OKT3
dose [7]. All subjects in these series were administered OKT3
as rejection prophylaxis at the time of transplantation.
The patient population in the current study differs from those
of Abramowicz et al and Chatenoud et al in several respects:
our patients were given OKT3 as therapy for acute rejection,
were receiving cyclosporine, and had been heavily pretreated
with methylprednisolone. The fact that many of our subjects
experienced pronounced first-dose reaction, the severity of
which correlated with TNFa levels in the absence of detectable
1L2 and IFNy, implicates TNFa as a primary etiologic agent of
first-dose reaction. Although our sampling time of two hours
may have been too early to detect peak elevations of 1L2 and
IFNy, it seems unlikely that any delayed increase in the levels
of these cytokines would contribute to symptomatology occur-
ring within 30 minutes to two hours after OKT3 administration.
We instead postulate that secretion of 1L2 and IFN7 was
suppressed by the combination of CsA and corticosteroids. In
addition, our peak TNFa levels approximate the lower levels
reported by other investigators in the presence of high-dose
corticosteroids, again suggesting an effect of concomitant im-
munosuppressive agents [7, 19]. Indeed, the contrasting reac-
tions between patients in Groups 1 and 2 may reflect differing
responses to prior immunosuppression. Hirsch, Gress and
Bluestone have suggested that use of OKT3 as treatment of
autoimmune diseases in patients not receiving prior immuno-
suppression may result in more severe side effects, and should
be approached cautiously [38]. Our results support this recom-
mendation.
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Normal total lymphocyte counts range from 1200 to 1500
cells/pd. Our patients, with a mean count of 637 cells/sl, were
relatively lymphopenic before OKT3 therapy was started, pre-
sumably, again, reflecting prior immunosuppression. The find-
ings of marked neutrophilia and profound lymphopenia within
two hours of OKT3 administration are identical to those of
Ulich and coworkers, who studied rats following infusion of
recombinant TNFa [27]. These investigators found that, within
ninety minutes of TNFa administration, significant neutrophilia
and lymphopenia were evident. Counts were noted to have
returned to normal by 24 hours, but similar responses occurred
with repeated injections of TNFa. In the current study, stimu-
lation of TNFa secretion by OKT3 may have contributed to
early changes in these hematologic parameters as well, with
more persistent changes in lymphocyte counts due to other
mechanisms.
Despite similar total lymphocyte counts in the two study
groups, greater numbers of circulating CD3+ and CD4+ T cells
in Group 2 patients may have predisposed them to more severe
first-dose reactions. Although this study provides no direct
evidence of T cell stimulation, our data, with selective elevation
of TNFa levels, support a role for immune activation rather
than cell lysis as the underlying mechanism of such reactions.
Nonspecific lysis of all CD3+ cells would appear unlikely to
result in such a limited cytokine profile, and would not explain
selective inhibition of 1L2 and IFNy production by CsA and/or
corticosteroids. Although TNFa is typically derived from stim-
ulated cells of monocyte/macrophage lineage [391, several in-
vestigators have found T cells to be capable of TNFa release.
Sung and colleagues [40] reported that T lymphocyte TNFa
production could be induced by OKT3, in the absence of
monocytes (using phorbol ester to bypass monocyte-mediated
cross linking of Fc segments of OKT3). Skolnik and coworkers
[41] found membrane-bound TNFa on activated T cells, the
presence of which was abolished by pretreatment with CsA
and/or corticosteroids. In the current study, there was a trend
toward lower CsA levels in Group 2 subjects, who demon-
strated greater elevation of TNFa levels post-OKT3. Since CsA
is known to have little effect on macrophage effector functions
[36], these data seem consistent with a T lymphocyte source for
TNFa. Conversely, other investigators have published data
showing that TNFa is released by circulating monocytes during
the process of opsonization and phagocytosis [421, which is
presumed to occur following OKT3 administration [31]. Thus,
no definite conclusion may yet be reached regarding the cellular
source of this cytokine post-OKT3 infusion.
It is thus conceivable that first-dose reaction may result from
OKT3-induced stimulation of circulating T lymphocytes and is
mediated by TNFa, which rises to higher levels in patients with
greater numbers of CD3+ and CD4+ cells at the time OKT3 is
given. We and others [1, 2, 6], however, have observed patients
with severe reactions after the second or third dose of OKT3, a
time when the number of circulating CD3+ and CD4+ cells was
negligible. In addition, Abramowicz et al [18] and Chatenoud et
al [19] have not found cytokine levels to increase after second
and third OKT3 doses. (We did not measure levels other than
after the first dose.) Therefore, additional mediators and mech-
anisms may contribute to the side effects observed with OKT3
administration. Chatenoud and coworkers 1431 measured inter-
leukin-l/3, interferon-a, and granulocyte/macrophage colony-
stimulating factor (GM-CSF): these were not increased post-
OKT3. The time course of first-dose reaction would appear to
make tumor necrosis factor /3 (which in vitro and in vivo
reaches peak levels at 8 to 24 hours following stimulation [40,
441 an unlikely culprit, although a role for this and other
cytokines, such as interleukin 6, has not been excluded. As
previously noted, other cell lines may be involved as well, via
putative mechanisms such as activation of monocytes by inter-
action between OKT3 Fc domains and macrophage Fc recep-
tors [32, 45].
Corticosteroids have been used to lessen the severity of the
OKT3 first-dose reaction [46]. However, the study by Goldman
and coworkers [7] showed that despite reduction of peak
TNFa, 1L2, and IFNy levels by premedication with high-dose
corticosteroids, first-dose reaction was still present in most
OKT3 recipients. Our results indicate that preventive therapy
directed primarily at TNFa and its effects might more effec-
tively diminish symptoms. in a mouse model, Goldman et al
[21] found that prior administration of anti-TNFa mAb essen-
tially abolished the first-dose reaction. Since many cellular
effects of TNFa appear to be mediated by products of cyclo-
oxygenase pathways [25, 47, 48], non-steroidal anti-inflamma-
tory agents might also offer some efficacy in this regard.
in conclusion, we have documented correlation between
OKT3 first-dose reaction and serum levels of TNFa in humans
allograft recipients undergoing "quadruple" immunosuppres-
sion. We also have noted a link between the severity of the
clinical syndrome and numbers of circulating CD3+ and CD4+
lymphocytes prior to OKT3 administration, and suggest a role
for T cell activation rather than lysis as the principal mechanism
underlying these events. Studies of intervention directed at
TNFa in order to attenuate first-dose reaction appear war-
ranted.
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